Hematogic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, United States.
Cancer Research and Biostatistics, Seattle, Washington, United States.
Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.
multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease response.
PATIENTS & METHODS: this was a multi-institutional, international, retrospective analysis of high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials. Clinical variable and survival data were collected from 7291 MM patients from Czech Republic, France, Germany, Italy, Korea, Spain, the Nordic Myeloma Study Group and the United States. Kaplan-Meier curves were used to assess progression-free survival (PFS) and overall survival (OS). Relative survival (RS) and statistical cure fractions (CF) were computed for all patients with available data.
achieving CR at 1 year was associated with superior PFS (median PFS 3.3 years vs. 2.6 years, p < 0.0001) as well as OS (median OS 8.5 years vs. 6.3 years, p < 0.0001). Clinical variables at diagnosis associated with 5-year survival and 10-year survival were compared with those associated with 2-year death. In multivariate analysis, age over 65 years (OR 1.87, p = 0.002), IgA Isotype (OR 1.53, p = 0.004), low albumin < 3.5 g/dL (OR = 1.36, p = 0.023), elevated beta 2 microglobulin ≥ 3.5 mg/dL (OR 1.86, p < 0.001), serum creatinine levels ≥ 2 mg/dL (OR 1.77, p = 0.005), hemoglobin levels < 10 g/dL (OR 1.55, p = 0.003), and platelet count < 150k/μL (OR 2.26, p < 0.001) appeared to be negatively associated with 10-year survival. The relative survival for the cohort was ~0.9, and the statistical cure fraction was 14.3%.
these data identify CR as an important predictor of long-term survival for HDM-ASCT eligible MM patients. They also identify clinical variables reflective of higher disease burden as poor prognostic markers for long-term survival.
多发性骨髓瘤被认为是一种无法治愈的血液系统癌症,但有一部分患者可以实现长期缓解和生存。本研究检查了与疾病缓解深度相关的长期生存的临床特征。
这是一项多机构、国际、回顾性分析,纳入了临床试验中接受高剂量马法兰自体干细胞移植(HDM-ASCT)的多发性骨髓瘤患者。从捷克共和国、法国、德国、意大利、韩国、西班牙、北欧骨髓瘤研究组和美国的 7291 名多发性骨髓瘤患者中收集了临床变量和生存数据。使用 Kaplan-Meier 曲线评估无进展生存期(PFS)和总生存期(OS)。对于所有有可用数据的患者,计算相对生存期(RS)和统计治愈率(CF)。
在 1 年内达到完全缓解(CR)与更好的 PFS(中位 PFS 3.3 年 vs. 2.6 年,p<0.0001)和 OS(中位 OS 8.5 年 vs. 6.3 年,p<0.0001)相关。与 2 年死亡相关的诊断时临床变量与 5 年生存率和 10 年生存率进行了比较。多变量分析显示,年龄大于 65 岁(OR 1.87,p=0.002)、IgA 同种型(OR 1.53,p=0.004)、白蛋白水平低(<3.5g/dL,OR=1.36,p=0.023)、β2 微球蛋白水平升高(≥3.5mg/dL,OR 1.86,p<0.001)、血清肌酐水平升高(≥2mg/dL,OR 1.77,p=0.005)、血红蛋白水平降低(<10g/dL,OR 1.55,p=0.003)和血小板计数降低(<150k/μL,OR 2.26,p<0.001)似乎与 10 年生存率呈负相关。该队列的相对生存率约为 0.9,统计学治愈率为 14.3%。
这些数据表明,CR 是 HDM-ASCT 适合的多发性骨髓瘤患者长期生存的重要预测指标。它们还确定了反映更高疾病负担的临床变量作为长期生存的不良预后标志物。